Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Tocilizumab biosimilar - Outlook Therapeutics

Next Previous
Drug Profile

Tocilizumab biosimilar - Outlook Therapeutics

Alternative Names: ONS-3030

Latest Information Update: 05 Sep 2023

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Oncobiologics
  • Developer Outlook Therapeutics
  • Class Anti-inflammatories; Antineoplastics; Antirheumatics; Antivirals; Immunotherapies; Monoclonal antibodies; Skin disorder therapies; Urologics; Vascular disorder therapies
  • Mechanism of Action Immunosuppressants; Interleukin 6 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Discontinued Ankylosing spondylitis; Chronic lymphocytic leukaemia; Crohn's disease; Dermatomyositis; Giant lymph node hyperplasia; Juvenile rheumatoid arthritis; Multiple myeloma; Pancreatic cancer; Polymyositis; Rheumatoid arthritis

Most Recent Events

  • 04 Sep 2023 Discontinued - Preclinical for Ankylosing spondylitis in USA (IV) (Outlook Therapeutics pipeline, September 2023)
  • 04 Sep 2023 Discontinued - Preclinical for Chronic lymphocytic leukaemia in USA (IV) (Outlook Therapeutics pipeline, September 2023)
  • 04 Sep 2023 Discontinued - Preclinical for Crohn's disease in USA (IV) (Outlook Therapeutics pipeline, September 2023)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top